R Squared’s C4 Therapeutics CCCC Stock Holding History

R Squared’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,674	Closed	-$26.1K	–	516
2025 Q4	$26.1K	Sell	13,674 -4,206	-24%	-$9.96K	0.01%	484
2025 Q3	$39.7K	Sell	17,880 -12,707	-42%	-$30.5K	0.02%	506
2025 Q2	$43.7K	Buy	+30,587	New	+$44.5K	0.02%	402
2025 Q1	–	Sell	-3,310	Closed	-$11.9K	–	506
2024 Q4	$11.9K	Buy	+3,310	New	+$16.5K	0.01%	1090

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

R Squared's CCCC Position: Q1 2026 in Review

R Squared sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 13,674 shares — an estimated $26.1K sold.

R Squared first reported a position in CCCC in Q4 2024 and held it in 4 quarters. The position peaked at $43.7K in Q2 2025. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

R Squared reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
R Squared sold 13,674 C4 Therapeutics shares in Q1 2026, an estimated $26.1K.
R Squared first reported a position in C4 Therapeutics in Q4 2024 and held it in 4 quarters.
R Squared's C4 Therapeutics position peaked at $43.7K in Q2 2025.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.